Review





Similar Products

94
Miltenyi Biotec anti mouse sirpα pe antibody
Anti Mouse Sirpα Pe Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/CD172a+(SIRP%CE%B1)+Antibody%2C+anti-mouse%2C+REAfinity/pm42323948-73-75-78
Average 94 stars, based on 1 article reviews
anti mouse sirpα pe antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Sino Biological human sirpα v1 mfc
Human Sirpα V1 Mfc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/Human+SIRP+alpha+%2F+CD172a+Protein/us12577303-449-4-6
Average 94 stars, based on 1 article reviews
human sirpα v1 mfc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Bio X Cell anti sirpα antibody
Anti Sirpα Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/InVivoMAb+anti-mouse+CD172a/pm42901146-411-56-60
Average 94 stars, based on 1 article reviews
anti sirpα antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Novus Biologicals ox 41
Antibodies used for in vitro investigations.
Ox 41, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP+alpha%2FCD172a+Antibody+-+BSA+Free/pmc13626330-10-0-6
Average 94 stars, based on 1 article reviews
ox 41 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Twist Bioscience sirpα fc
( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of <t>the</t> <t>SIRPα-Fc</t> molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.
Sirpα Fc, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP+alpha/pmc13469128-440-10-18
Average 94 stars, based on 1 article reviews
sirpα fc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Synthego Inc sirpα single guide rna
( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of <t>the</t> <t>SIRPα-Fc</t> molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.
Sirpα Single Guide Rna, supplied by Synthego Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/guide+rna+single+sirp%CE%B1/pm42320470-695-16-19
Average 86 stars, based on 1 article reviews
sirpα single guide rna - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
OriGene sirp alpha sirpa human gene knockout kit
( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of <t>the</t> <t>SIRPα-Fc</t> molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.
Sirp Alpha Sirpa Human Gene Knockout Kit, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/SIRP+alpha+(SIRPA)+Human+Gene+Knockout+Kit/pm42213780-175-8-17
Average 94 stars, based on 1 article reviews
sirp alpha sirpa human gene knockout kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

92
Miltenyi Biotec cd172a (sirpα) antibody, anti-human, reafinity
( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of <t>the</t> <t>SIRPα-Fc</t> molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.
Cd172a (Sirpα) Antibody, Anti Human, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/CD172a+(SIRP%CE%B1)+Antibody%2C+anti-human%2C+REAfinity/custom%40130-122-330%4041881840
Average 92 stars, based on 1 article reviews
cd172a (sirpα) antibody, anti-human, reafinity - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

94
Sino Biological h08h
( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of <t>the</t> <t>SIRPα-Fc</t> molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.
H08h, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/Human+SIRP+alpha+%2F+CD172a+Protein/us12577303-368-7-0
Average 94 stars, based on 1 article reviews
h08h - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Sino Biological human sirpα v1
( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of <t>the</t> <t>SIRPα-Fc</t> molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.
Human Sirpα V1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirp%CE%B1/Human+SIRP+alpha+%2F+CD172a+Protein/us12577303-368-3-0
Average 94 stars, based on 1 article reviews
human sirpα v1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


Antibodies used for in vitro investigations.

Journal: PLOS One

Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

doi: 10.1371/journal.pone.0359269

Figure Lengend Snippet: Antibodies used for in vitro investigations.

Article Snippet: OX-41 , Rabbit , Monoclonal , Novus , NBP1–03074 , – , 4.

Techniques: In Vitro

ICC analysis of cultures shows the total number of TH(+) neurons (A) and the length of their neurite network neurons (B) and microglia activation as area of OX-41(+) staining (C), expressed as % of control. Raw values for control (CTR) (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 81 ± 4.0; neurite network = 2332 ± 112 µm; OX-41(+) area/field = 1421 ± 67 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; **p < 0.01, ***p < 0.001 and ****p < 0.0001 from α-syn injury, (n = 4-6 / group).

Journal: PLOS One

Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

doi: 10.1371/journal.pone.0359269

Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A) and the length of their neurite network neurons (B) and microglia activation as area of OX-41(+) staining (C), expressed as % of control. Raw values for control (CTR) (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 81 ± 4.0; neurite network = 2332 ± 112 µm; OX-41(+) area/field = 1421 ± 67 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; **p < 0.01, ***p < 0.001 and ****p < 0.0001 from α-syn injury, (n = 4-6 / group).

Article Snippet: OX-41 , Rabbit , Monoclonal , Novus , NBP1–03074 , – , 4.

Techniques: Analysis, Activation Assay, Staining, Control

( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of the SIRPα-Fc molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) Schematic representation of the encoded IgA molecules and the corresponding pShuttle expression vector scheme maps are shown. Black: promoter (CMV); green: leader sequence from rituximab; red, orange: VH and VL variable domains of the heavy and light chain of IgA, respectively; gray: furin recognition sequence, followed by a P2A or T2A “self-cleaving” (ribosome skipping) sequence (yellow); the cleavage site is indicated schematically; blue and cyan: heavy chain and light chain of IgA with the respective CH1-CH3 heavy and VL light chain domains. Dimeric IgA was encoded in the same vector format with a modified CH3 domain (introduced C-terminal Cys-Tyr (CY) residues), with the joining (J-) chain (magenta) encoded under EMCV IRES sequence (light gray). ( B ) Schematic representation of the SIRPα-Fc molecule and the respective expression vector map. Black: EF-1α promoter; green: SIRPα leader sequence; pink: Consensus variant (CV) of D1 domain of SIRPα engineered with increased affinity to human CD47 and cross-reactivity with murine CD47; blue: Fc-ablated, AAA-mutant variant of the IgG1 heavy chain CH2-CH3 domains. RTX rituximab.

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Expressing, Plasmid Preparation, Sequencing, Modification, Variant Assay, Mutagenesis

( A ) ELISA was used to measure the target-binding activity of anti-EGFR and anti-EpCAM IgA antibodies derived from the supernatants of transfected CHO-S cells. Recombinant IgA and IgG antibodies were used as positive controls (ctrl: 0.1 nM), and supernatants from mock-transfected cells served as negative controls. Binding specificity was confirmed by assessing the binding of each IgA antibody to its intended target (EGFR or EpCAM) and to the non-target protein. ( B ) Western blot analysis of anti-EGFR and anti-EpCAM IgA antibodies in the supernatant of transfected CHO-S cells (lane 1,3). Purified recombinant IgA antibodies were used as controls (lane 2,4). Note that the anti-EGFR IgA control shows incomplete antibody assembly, and that the running behaviors of proteins from supernatants are slightly different from those of purified proteins. HC heavy chain, LC light chain. Reduced and non-reduced conditions are depicted. The same membrane was used for top and bottom blots, which were stained with two distinct antibodies. ( C ) Western blot analysis of dimeric IgA antibodies under non-reducing conditions, showing the presence of both the IgA heavy chain (HC), detected by a mouse anti-human kappa chain antibody, and the J-chain (JC), detected by a mouse anti-poly His-tag antibody, in supernatants of CHO-S transiently transfected with the respective expression vectors. 1: anti-EGFR; 2: anti-EpCAM. ( D ) ELISA was performed to measure SIRPα-Fc protein levels in the supernatant of transfected CHO-S cells, using CD47 as coating. A recombinant anti-CD47 IgG antibody (2.5 nM) was used as a positive control, and supernatant from mock-transfected cells served as a negative control. Wells with no CD47 coating served as additional controls. ( E ) Western blot analysis of the SIRPα-Fc protein, as detected by a mouse anti-γ heavy chain, in supernatants of CHO-S cells transiently transfected with the respective expression vector, under reducing (red) and non-reducing (non-red) conditions. ( A , D ) Representative ELISA data from three independent biological replicates. Bars represent individual values ( n = 1) or the mean of technical replicates ( n = 2). ( B , C , E ) Representative images from three independent biological replicates. .

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) ELISA was used to measure the target-binding activity of anti-EGFR and anti-EpCAM IgA antibodies derived from the supernatants of transfected CHO-S cells. Recombinant IgA and IgG antibodies were used as positive controls (ctrl: 0.1 nM), and supernatants from mock-transfected cells served as negative controls. Binding specificity was confirmed by assessing the binding of each IgA antibody to its intended target (EGFR or EpCAM) and to the non-target protein. ( B ) Western blot analysis of anti-EGFR and anti-EpCAM IgA antibodies in the supernatant of transfected CHO-S cells (lane 1,3). Purified recombinant IgA antibodies were used as controls (lane 2,4). Note that the anti-EGFR IgA control shows incomplete antibody assembly, and that the running behaviors of proteins from supernatants are slightly different from those of purified proteins. HC heavy chain, LC light chain. Reduced and non-reduced conditions are depicted. The same membrane was used for top and bottom blots, which were stained with two distinct antibodies. ( C ) Western blot analysis of dimeric IgA antibodies under non-reducing conditions, showing the presence of both the IgA heavy chain (HC), detected by a mouse anti-human kappa chain antibody, and the J-chain (JC), detected by a mouse anti-poly His-tag antibody, in supernatants of CHO-S transiently transfected with the respective expression vectors. 1: anti-EGFR; 2: anti-EpCAM. ( D ) ELISA was performed to measure SIRPα-Fc protein levels in the supernatant of transfected CHO-S cells, using CD47 as coating. A recombinant anti-CD47 IgG antibody (2.5 nM) was used as a positive control, and supernatant from mock-transfected cells served as a negative control. Wells with no CD47 coating served as additional controls. ( E ) Western blot analysis of the SIRPα-Fc protein, as detected by a mouse anti-γ heavy chain, in supernatants of CHO-S cells transiently transfected with the respective expression vector, under reducing (red) and non-reducing (non-red) conditions. ( A , D ) Representative ELISA data from three independent biological replicates. Bars represent individual values ( n = 1) or the mean of technical replicates ( n = 2). ( B , C , E ) Representative images from three independent biological replicates. .

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Activity Assay, Derivative Assay, Transfection, Recombinant, Western Blot, Purification, Control, Membrane, Staining, Expressing, Positive Control, Negative Control, Plasmid Preparation

( A ) Schematic image showing the retargeting approach of the adenovirus. The adenovirus capsid is composed of hexons forming its main shell, pentons anchoring at the vertices, and fibers projecting from those vertices for host cell attachment. As reported in previous work, a trimeric DARPin (orange) can be engineered to cover the free knob at the tip of each fiber of the adenovirus in order to achieve retargeting (Dreier et al, ). ( B , C ) Monomeric anti-EpCAM IgA and anti-EGFR IgA were produced in HCT116 ( B ) and MDA-MB-468 cells ( C ), respectively, via retargeting of the AdV vector to EGFR or EpCAM using the DARPin-based approach described in ( A ). Green, AdV payload (IgA, labeled by anti-kappa-light chain, or SIRPα-Fc, labeled by anti-human IgG. Secondary antibodies were Alexa-488 labeled); cyan, nuclei (Hoechst). MOI: 50 i.v.p./cell (IgA), 5 i.v.p./cell (SIRPα-Fc). Please note that control panels for MDA-MB-468 (labeled NT) are also utilized in Appendix Fig. . ( D ) Comparison of adenovirus-mediated co-delivery of IgA and SIRPα-Fc when retargeting the respective adenovirus to EpCAM or EGFR (EpCAM- or EGFR-retarg) on the surface of the cancer cells (HCT116), which express both receptors. ( E ) Anti-EpCAM IgA dimer was delivered via EpCAM-retargeted AdV in HCT116 cells. J-chain (magenta) was detected in the dimer-transduced sample, and co-localized with IgA (green) signal. Cyan, nuclei (Hoechst). Positive controls (recombinant IgA, SIRPα-Fc proteins) and secondary Ab-only control images are shown in Appendix Fig. . All cells are non-permeabilized, meaning products we see have been secreted from the cells and re-bind from the outside in an autocrine or paracrine fashion. Representative images from two independent biological replicates are shown. NT non-treated. Scale bars: 100 μm. .

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) Schematic image showing the retargeting approach of the adenovirus. The adenovirus capsid is composed of hexons forming its main shell, pentons anchoring at the vertices, and fibers projecting from those vertices for host cell attachment. As reported in previous work, a trimeric DARPin (orange) can be engineered to cover the free knob at the tip of each fiber of the adenovirus in order to achieve retargeting (Dreier et al, ). ( B , C ) Monomeric anti-EpCAM IgA and anti-EGFR IgA were produced in HCT116 ( B ) and MDA-MB-468 cells ( C ), respectively, via retargeting of the AdV vector to EGFR or EpCAM using the DARPin-based approach described in ( A ). Green, AdV payload (IgA, labeled by anti-kappa-light chain, or SIRPα-Fc, labeled by anti-human IgG. Secondary antibodies were Alexa-488 labeled); cyan, nuclei (Hoechst). MOI: 50 i.v.p./cell (IgA), 5 i.v.p./cell (SIRPα-Fc). Please note that control panels for MDA-MB-468 (labeled NT) are also utilized in Appendix Fig. . ( D ) Comparison of adenovirus-mediated co-delivery of IgA and SIRPα-Fc when retargeting the respective adenovirus to EpCAM or EGFR (EpCAM- or EGFR-retarg) on the surface of the cancer cells (HCT116), which express both receptors. ( E ) Anti-EpCAM IgA dimer was delivered via EpCAM-retargeted AdV in HCT116 cells. J-chain (magenta) was detected in the dimer-transduced sample, and co-localized with IgA (green) signal. Cyan, nuclei (Hoechst). Positive controls (recombinant IgA, SIRPα-Fc proteins) and secondary Ab-only control images are shown in Appendix Fig. . All cells are non-permeabilized, meaning products we see have been secreted from the cells and re-bind from the outside in an autocrine or paracrine fashion. Representative images from two independent biological replicates are shown. NT non-treated. Scale bars: 100 μm. .

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Cell Attachment Assay, Produced, Plasmid Preparation, Labeling, Control, Comparison, Recombinant

SIRPα-Fc and Anti-EGFR IgA and anti-EpCAM IgA were produced in MDA-MB-468 ( A , C ) and HCT116 cells ( B ) upon retargeting of the AdV vector to either EpCAM or EGFR, respectively. Cells were labeled with cell-permeant non-fluorescent CellTrace dyes, which react with amino groups and become fluorescent. Yellow, population one of the tumor cells (P1, labeled cell population) transduced with AdV in the respective samples; cyan, nuclei (Hoechst, both populations); magenta, IgA (detected by goat anti-human kappa light chain); green, SIRPα-Fc (detected by goat anti-human IgG Fc). The merged images (cyan and yellow) show the overlay between the nuclei (both populations) and the transduced cells (P1). Staining of IgA or SIRPα-Fc in non-yellow areas indicates binding to non-transduced cells in a paracrine fashion. Scale bar: 100 μm. Please note that control panels for MDA-MB-468 (labeled NT) are also utilized in Appendix Fig. . ( C ) A close-up of MDA-MB-468 cells producing IgA and SIRPα-Fc in a paracrine fashion. Cells were not permeabilized before staining. NT, non-treated. Scale bar: 50 μm. Positive controls (purified recombinant IgA, SIRPα-Fc proteins) and secondary Ab-only control images are shown in Appendix Fig. . MOI: 20 i.v.p./cell (each virus). Representative images from three biological replicates are shown.

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: SIRPα-Fc and Anti-EGFR IgA and anti-EpCAM IgA were produced in MDA-MB-468 ( A , C ) and HCT116 cells ( B ) upon retargeting of the AdV vector to either EpCAM or EGFR, respectively. Cells were labeled with cell-permeant non-fluorescent CellTrace dyes, which react with amino groups and become fluorescent. Yellow, population one of the tumor cells (P1, labeled cell population) transduced with AdV in the respective samples; cyan, nuclei (Hoechst, both populations); magenta, IgA (detected by goat anti-human kappa light chain); green, SIRPα-Fc (detected by goat anti-human IgG Fc). The merged images (cyan and yellow) show the overlay between the nuclei (both populations) and the transduced cells (P1). Staining of IgA or SIRPα-Fc in non-yellow areas indicates binding to non-transduced cells in a paracrine fashion. Scale bar: 100 μm. Please note that control panels for MDA-MB-468 (labeled NT) are also utilized in Appendix Fig. . ( C ) A close-up of MDA-MB-468 cells producing IgA and SIRPα-Fc in a paracrine fashion. Cells were not permeabilized before staining. NT, non-treated. Scale bar: 50 μm. Positive controls (purified recombinant IgA, SIRPα-Fc proteins) and secondary Ab-only control images are shown in Appendix Fig. . MOI: 20 i.v.p./cell (each virus). Representative images from three biological replicates are shown.

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Produced, Plasmid Preparation, Labeling, Transduction, Staining, Binding Assay, Control, Purification, Recombinant, Virus

( A ) A schematic image of the previously described tumor-on-a-chip (not drawn to scale) and experimental workflow. The design consists of a main chamber for co-culturing of multiple cell types in a collagen matrix, and two side channels with medium reservoirs through which retargeted adenoviral vectors or control proteins are administered (Palacio-Castaneda et al, ). The approximate areas of the chip of the respective microscopy images are shown (blue: C – E ; red: F , G ). ( B ) A photograph of the polydimethylsiloxane (PDMS) microfluidic device with the inset depicting the region where cells grow. Cells were stained with different CellTrace dyes, and proteins were detected with fluorescently labeled antibodies. ( C ) Anti-EpCAM IgA or anti-EGFR IgA (Payload, magenta) was locally produced in the TME featuring MDA-MB-468 or HCT116 cells (Cancer cells, yellow), respectively, as well as fibroblasts (green) and endothelial cells (cyan). IgA-encoding adenoviruses were retargeted with the respective adapters to EGFR or EpCAM expressed on HCT116 or MDA-MB-468 cells, respectively, at an MOI of 20 i.v.p./cell. ( D ) Similar to ( A ), SIRPα-Fc was produced in situ upon AdV retargeting to EGFR (HCT116) or EpCAM (MDA-MB-468) at an MOI of 20 i.v.p./cell. The overlay image shows no specificity of SIRPα-Fc towards either of the cell types, due to ubiquitous expression of CD47 on all cells. ( E ) Anti-EGFR IgA (magenta) and SIRPα-Fc (green) simultaneously produced in situ upon co-delivery with EpCAM-retargeted adenoviral vectors in MDA-MB-468 (nuclei: cyan, Hoechst) at an MOI of 20 i.v.p./cell (each). Merge depicts SIRPα-Fc and IgA. ( F ) Adenovirus-mediated co-delivery of IgA and SIRPα-Fc as in ( E ), represented as orthogonal sections showing 3D distribution of cells with the in situ produced payloads on the cell surface, with the 3D reconstruction shown in ( G ) (dimensions indicated). Positive controls (recombinant IgA, SIRPα-Fc) and secondary Ab-only control images are shown in Appendix Fig. . Representative images are shown, n = 4 biological replicates. Scale bars: 100 μm. .

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) A schematic image of the previously described tumor-on-a-chip (not drawn to scale) and experimental workflow. The design consists of a main chamber for co-culturing of multiple cell types in a collagen matrix, and two side channels with medium reservoirs through which retargeted adenoviral vectors or control proteins are administered (Palacio-Castaneda et al, ). The approximate areas of the chip of the respective microscopy images are shown (blue: C – E ; red: F , G ). ( B ) A photograph of the polydimethylsiloxane (PDMS) microfluidic device with the inset depicting the region where cells grow. Cells were stained with different CellTrace dyes, and proteins were detected with fluorescently labeled antibodies. ( C ) Anti-EpCAM IgA or anti-EGFR IgA (Payload, magenta) was locally produced in the TME featuring MDA-MB-468 or HCT116 cells (Cancer cells, yellow), respectively, as well as fibroblasts (green) and endothelial cells (cyan). IgA-encoding adenoviruses were retargeted with the respective adapters to EGFR or EpCAM expressed on HCT116 or MDA-MB-468 cells, respectively, at an MOI of 20 i.v.p./cell. ( D ) Similar to ( A ), SIRPα-Fc was produced in situ upon AdV retargeting to EGFR (HCT116) or EpCAM (MDA-MB-468) at an MOI of 20 i.v.p./cell. The overlay image shows no specificity of SIRPα-Fc towards either of the cell types, due to ubiquitous expression of CD47 on all cells. ( E ) Anti-EGFR IgA (magenta) and SIRPα-Fc (green) simultaneously produced in situ upon co-delivery with EpCAM-retargeted adenoviral vectors in MDA-MB-468 (nuclei: cyan, Hoechst) at an MOI of 20 i.v.p./cell (each). Merge depicts SIRPα-Fc and IgA. ( F ) Adenovirus-mediated co-delivery of IgA and SIRPα-Fc as in ( E ), represented as orthogonal sections showing 3D distribution of cells with the in situ produced payloads on the cell surface, with the 3D reconstruction shown in ( G ) (dimensions indicated). Positive controls (recombinant IgA, SIRPα-Fc) and secondary Ab-only control images are shown in Appendix Fig. . Representative images are shown, n = 4 biological replicates. Scale bars: 100 μm. .

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Control, Microscopy, Staining, Labeling, Produced, In Situ, Expressing, Recombinant

( A ) Results of the ADCC assay on-chip showing the activity of primary human neutrophils in killing MDA-MB-468 and A-431 cells via AdV-delivered, in situ produced anti-EGFR IgA (monomer, mIgA or dimer, dIgA), compared to the combination with the SIRPα-Fc co-delivered with the respective IgA. Administration of the SIRPα-Fc alone was tested as a control condition, and non-treated cancer cells with neutrophils alone were used as a negative control. Mean and SEM are shown; data shown for n = 5 biological replicates from three donors (MDA-MB-468) and n = 3 biological replicates from one donor (A-431). Statistical analysis: unpaired t test, adjusted P values are shown. ( B ) Results of the ADCP assay on-chip showing the relative phagocytic index of macrophages (MФ) in MDA-MB-468 cells upon treatment with anti-EGFR IgA alone or in combination with the SIRPα-Fc, delivered via retargeted adenoviruses. Non-treated cancer cell-macrophage co-cultures were used as a control (MФ only); adenovirus encoding eGFP (mock) was used as a vehicle control. As a positive control for the maximum phagocytic activity, a combination of recombinant anti-EGFR IgA at 1 nM and SIRPα-Fc at 0.5 nM was used (prot. ctrl). Administration of the SIRPα-Fc alone was tested as an additional control condition. Mean, range, interquartile range, and individual values are shown to indicate the level of variability, data for n = 5 biological replicates from three different batches of monocyte-derived macrophages (from pooled donors). Statistical analysis: one-way ANOVA with Dunnett’s correction for multiple comparisons, adjusted P values are shown. In both assays, MOI used: anti-EGFR IgA-encoding vector: 50 i.v.p./cell; SIRPα-Fc-encoding vector: 5 i.v.p./cell. .

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) Results of the ADCC assay on-chip showing the activity of primary human neutrophils in killing MDA-MB-468 and A-431 cells via AdV-delivered, in situ produced anti-EGFR IgA (monomer, mIgA or dimer, dIgA), compared to the combination with the SIRPα-Fc co-delivered with the respective IgA. Administration of the SIRPα-Fc alone was tested as a control condition, and non-treated cancer cells with neutrophils alone were used as a negative control. Mean and SEM are shown; data shown for n = 5 biological replicates from three donors (MDA-MB-468) and n = 3 biological replicates from one donor (A-431). Statistical analysis: unpaired t test, adjusted P values are shown. ( B ) Results of the ADCP assay on-chip showing the relative phagocytic index of macrophages (MФ) in MDA-MB-468 cells upon treatment with anti-EGFR IgA alone or in combination with the SIRPα-Fc, delivered via retargeted adenoviruses. Non-treated cancer cell-macrophage co-cultures were used as a control (MФ only); adenovirus encoding eGFP (mock) was used as a vehicle control. As a positive control for the maximum phagocytic activity, a combination of recombinant anti-EGFR IgA at 1 nM and SIRPα-Fc at 0.5 nM was used (prot. ctrl). Administration of the SIRPα-Fc alone was tested as an additional control condition. Mean, range, interquartile range, and individual values are shown to indicate the level of variability, data for n = 5 biological replicates from three different batches of monocyte-derived macrophages (from pooled donors). Statistical analysis: one-way ANOVA with Dunnett’s correction for multiple comparisons, adjusted P values are shown. In both assays, MOI used: anti-EGFR IgA-encoding vector: 50 i.v.p./cell; SIRPα-Fc-encoding vector: 5 i.v.p./cell. .

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: ADCC Assay, Activity Assay, In Situ, Produced, Control, Negative Control, Positive Control, Recombinant, Derivative Assay, Plasmid Preparation

( A ) Schematic image of the experimental workflow. ( B ) Anti-EpCAM IgA, or anti-EGFR IgA, together with SIRPα-Fc, were locally produced upon adenoviral transduction (AdV) in HCT116 and MDA-MB-468 tumor models, respectively. In each model, the respective cancer cells were labeled (magenta, CellTrace Far Red) and co-cultured on-chip with labeled healthy fibroblasts (cyan, CellTrace Violet). Following adenoviral transduction, the ADCC assay with primary human neutrophils was performed as above, and the cell death was detected using a DNA-binding dye (CellTox Green). The overlay images are shown demonstrating specificity for cancer cell killing compared to fibroblasts. As positive controls, recombinant proteins were perfused on-chip, with anti-EGFR IgA and SIRPα-Fc (MDA-MB-468) at 1 nM and 0.5 nM, respectively, and anti-EpCAM IgA (HCT-116) at 5 nM. NT, negative control (non-treated co-culture with neutrophils added). Scale bar: 200 μm. Representative images are shown from four chips from two independent experiments (AdV samples: three chips). MOI: anti-EGFR IgA and anti-EpCAM IgA-encoding vectors: 50 i.v.p./cell; SIRPα-Fc-encoding vector: 5 i.v.p./cell. These MOI values were used in the functional assays as they achieved saturating signals of the payload expression. Please note that the green signal in the microtunnels likely corresponds to an accumulation of extracellular DNA from neutrophils, which is not taken into account in the analyses, as they rely on quantification of overlap with stained tumor cells. ( C ) Results of the ADCC assay on-chip, quantification performed per cell type for killing specificity. AdV, adenovirus-based delivery of anti-EpCAM IgA (in HCT116 model) or anti-EGFR IgA with SIRPα-Fc (in MDA-MB-468 model); Protein ctrl, respective recombinant protein controls perfused on-chip at 5 nM; NT, non-treated co-cultures to which neutrophils were added. Protein Ctrl (purified anti-EGFR IgA (left) or anti-EpCAM IgA (right)): n = 2 biological replicates; AdV: n = 3 biological replicates. Means with SEM are shown. Statistical analysis: unpaired t test with the P values adjusted for multiple comparisons indicated. .

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) Schematic image of the experimental workflow. ( B ) Anti-EpCAM IgA, or anti-EGFR IgA, together with SIRPα-Fc, were locally produced upon adenoviral transduction (AdV) in HCT116 and MDA-MB-468 tumor models, respectively. In each model, the respective cancer cells were labeled (magenta, CellTrace Far Red) and co-cultured on-chip with labeled healthy fibroblasts (cyan, CellTrace Violet). Following adenoviral transduction, the ADCC assay with primary human neutrophils was performed as above, and the cell death was detected using a DNA-binding dye (CellTox Green). The overlay images are shown demonstrating specificity for cancer cell killing compared to fibroblasts. As positive controls, recombinant proteins were perfused on-chip, with anti-EGFR IgA and SIRPα-Fc (MDA-MB-468) at 1 nM and 0.5 nM, respectively, and anti-EpCAM IgA (HCT-116) at 5 nM. NT, negative control (non-treated co-culture with neutrophils added). Scale bar: 200 μm. Representative images are shown from four chips from two independent experiments (AdV samples: three chips). MOI: anti-EGFR IgA and anti-EpCAM IgA-encoding vectors: 50 i.v.p./cell; SIRPα-Fc-encoding vector: 5 i.v.p./cell. These MOI values were used in the functional assays as they achieved saturating signals of the payload expression. Please note that the green signal in the microtunnels likely corresponds to an accumulation of extracellular DNA from neutrophils, which is not taken into account in the analyses, as they rely on quantification of overlap with stained tumor cells. ( C ) Results of the ADCC assay on-chip, quantification performed per cell type for killing specificity. AdV, adenovirus-based delivery of anti-EpCAM IgA (in HCT116 model) or anti-EGFR IgA with SIRPα-Fc (in MDA-MB-468 model); Protein ctrl, respective recombinant protein controls perfused on-chip at 5 nM; NT, non-treated co-cultures to which neutrophils were added. Protein Ctrl (purified anti-EGFR IgA (left) or anti-EpCAM IgA (right)): n = 2 biological replicates; AdV: n = 3 biological replicates. Means with SEM are shown. Statistical analysis: unpaired t test with the P values adjusted for multiple comparisons indicated. .

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Produced, Transduction, Labeling, Cell Culture, ADCC Assay, Binding Assay, CellTox Assay, Recombinant, Negative Control, Co-Culture Assay, Plasmid Preparation, Functional Assay, Expressing, Staining, Purification

( A ) Set-up of the in vivo study. ( B – E ) Immunofluorescence (IF) of tumor slices from MDA-MB-468 tumor-bearing SCID mice 4 days after injection with EpCAM-directed anti-EGFR IgA-encoding and SIRPα-Fc-encoding adenoviral vectors. Nuclei were stained with DAPI, and the produced anti-EGFR IgA was detected with a goat anti-Ckappa light chain. Ly6G and CD45 were detected in the same slice as markers for neutrophils and immune cells, respectively ( B ). EpCAM was detected to identify tumor cells with an anti-EpCAM antibody ( C ), SIRPα-Fc with goat anti-human Fc gamma ( D ), and CD47 with an anti-CD47 antibody ( E ). Scale bars ( B – E ): 200 μm. ( F ) A tile scan of a slice containing a full cross-section of the resected tumor was analyzed by IF for the condition described in ( B ) (left), or EpCAM (right), showing the distribution of the antibodies and infiltration of immune cells. Scale bar: 1 mm. n = 6 mice, representative images are shown. .

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: ( A ) Set-up of the in vivo study. ( B – E ) Immunofluorescence (IF) of tumor slices from MDA-MB-468 tumor-bearing SCID mice 4 days after injection with EpCAM-directed anti-EGFR IgA-encoding and SIRPα-Fc-encoding adenoviral vectors. Nuclei were stained with DAPI, and the produced anti-EGFR IgA was detected with a goat anti-Ckappa light chain. Ly6G and CD45 were detected in the same slice as markers for neutrophils and immune cells, respectively ( B ). EpCAM was detected to identify tumor cells with an anti-EpCAM antibody ( C ), SIRPα-Fc with goat anti-human Fc gamma ( D ), and CD47 with an anti-CD47 antibody ( E ). Scale bars ( B – E ): 200 μm. ( F ) A tile scan of a slice containing a full cross-section of the resected tumor was analyzed by IF for the condition described in ( B ) (left), or EpCAM (right), showing the distribution of the antibodies and infiltration of immune cells. Scale bar: 1 mm. n = 6 mice, representative images are shown. .

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: In Vivo, Immunofluorescence, Injection, Staining, Produced

IgA titers in plasma samples from tumor-bearing mice were measured by ELISA using monomeric IgA as a standard, with anti-human kappa light chain used for coating and anti-human IgA-HRP used for detection. Anti-EGFR IgA levels were detected upon treatment with ( A ) monomeric anti-EGFR IgA-encoding adenoviral vectors, ( B ) dimeric anti-EGFR IgA-encoding adenoviral vectors, ( C ) monomeric anti-EGFR IgA and SIRPα-Fc-encoding adenoviral vectors, or ( D ) vehicle control. Each symbol represents a different mouse.

Journal: EMBO Molecular Medicine

Article Title: Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy

doi: 10.1038/s44321-026-00477-7

Figure Lengend Snippet: IgA titers in plasma samples from tumor-bearing mice were measured by ELISA using monomeric IgA as a standard, with anti-human kappa light chain used for coating and anti-human IgA-HRP used for detection. Anti-EGFR IgA levels were detected upon treatment with ( A ) monomeric anti-EGFR IgA-encoding adenoviral vectors, ( B ) dimeric anti-EGFR IgA-encoding adenoviral vectors, ( C ) monomeric anti-EGFR IgA and SIRPα-Fc-encoding adenoviral vectors, or ( D ) vehicle control. Each symbol represents a different mouse.

Article Snippet: The expression cassettes for IgA2.0 (Lohse et al, ) and SIRPα-Fc (Kauder et al, ) were synthesized by Twist Bioscience (San Francisco, CA, USA) and cloned into the pShuttle vector via Gibson assembly (New England Biolabs, Ipswich, MA, USA).

Techniques: Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Control